Mark: The USDC ND FL Abilify MDL 2734 -- Global settlement fell through; 6 cases selected for trial and fast-track discovery. Trial scheduled for 2019 per original MDL trial schedule.
ABILIFY (ARIPIPRAZOL) MDL2734
US DISTRICT COURT
Northern District of Florida
Master Docket: 3:16-md-2734
On October 3, 2016, the JPML consolidated the Abilify (Aripiprazole) Products Liability Litigation, as ABILIFY (ARIPIPRAZOL) MDL2734 . The transferred actions share factual issues arising from allegations that Abilify (aripirazole), an atypical anti-psychotic medication commonly prescribed to treat a variety of mental disorders, can cause impulse control problems in users. All the actions involve factual questions of whether Abilify was defectively designed or manufactured, whether defendants knew or should have known of the alleged propensity of Abilify to cause compulsive gambling behaviors in users, and whether defendants provided adequate instructions and warnings with this product. These cases have been assigned to the Honorable M. Casey Rodgers for coordinated discovery and pretrial matters.
The Court has approved the use of MDL Centrality for service of Profile Forms and Fact Sheets in this MDL. The website for MDL Centrality is www.mdlcentrality.com/abilify(link is external). For attorneys needing assistance in setting up an account or general help, email firstname.lastname@example.org or call (888) 361-0741.